{
  "abstract": "Screening for oesophageal adenocarcinoma (OAC), a lethal cancer, when diagnosed after the onset of symptoms, and its sole known precursor, Barrett’s oesophagus (BO), though suggested by guidelines, remains underused.1 Support for screening is underpinned by level 1 evidence demonstrating the ability of endoscopic therapy of BO dysplasia to prevent progression to OAC and the excellent survival of patients with T1 OAC treated with endoscopic therapy.2",
  "authors": [
    {
      "affiliations": [
        "Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA"
      ],
      "name": "Prasad G Iyer"
    }
  ],
  "title": "EMERALD in the making? A promising blood-based microRNA panel to detect oesophageal adenocarcinoma and Barrett’s oesophagus",
  "uid": "4040562d-9ff3-52b2-8952-e090259c06fb"
}